Video
Dr. Spiess discusses differences in MTAP incidence and deletion across various tumors
Author(s):
“We need to look at tumors a little bit differently. Not so much put them in the same categories, but really look at them based on whether the mutation is as identified in that specific marker,” says Philippe E. Spiess, MD, MS, FRCSC, FACS.
In this video, Philippe E. Spiess, MD, MS, FRCSC, FACS, discusses the background and findings of the study, “Genomic classification of clinically advanced major genito-urinary cancers (GUca) based on methylthioadenosine phosphorylase (MTAP) genomic loss,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Spiess is a genitourinary oncologist and assistant chief of surgical services at the Moffitt Cancer Center in Tampa, Florida.
Related Videos
Related Content
